Edwards Lifesciences (EW) has updated its fiscal year 2025 financial outlook, projecting a revenue increase of 9% to 10% and showcasing strong financial health with robust margins. The company, a leader in medical devices specializing in structural heart disease treatments, provided this revised guidance at its annual investor conference. Despite positive analyst sentiment and strong financial indicators, a P/E ratio close to its 1-year high and recent insider selling activity suggest a mixed valuation picture.

爱德华生命科学

<p>爱德华生命科学 (EW) 更新了其 2025 财年的财务展望，预计收入增长 9% 至 10%，并展示了强劲的财务健康状况和稳健的利润率。该公司是专注于结构性心脏病治疗的医疗设备领域的领导者，在其年度投资者会议上提供了这一修订后的指引。尽管分析师情绪积极且财务指标强劲，但接近一年高点的市盈率和近期的内部人士卖出活动则暗示出一种混合的估值状况</p>

爱德华生命科学（EW）上调了 2025 财年的收入预测